Gebauer E, Tomić J, Stevanović S
Medicinski fakultet, Institut za zdravstvenu zastitu majke i deteta, Novi Sad.
Med Pregl. 1994 Jan-Feb;47(1-2):52-5.
Infections are a common cause of complications in the course of applying highly aggressive combined cytotoxic therapy in children suffering from acute leukemias (ALL and ANLL). The effect of adjuvant therapy of intravenous immunoglobulins (IVIG) was investigated in cases of infections of children with ALL and ANLL (24 with IVIG and 24 without this therapy) according to the system of matched pairs. The polyvalent functionally intact monomeric i.v. immunoglobulin "Endobulin" Immuno, 100 mg/kg was applied in infections--febrile episodes combined, if possible, with an aimed antibiotic therapy. It was established that children with the intravenous immunoglobulin therapy had had statistically significantly less febrile episodes (p < 0.01), as well as less febrile days (p < 0.05). Although the acquired results speak in favor of this therapeutic possibility when applying this supportive therapy which is getting more and more important, authors made a conclusion that the final estimate of the value of this therapy remains open and requires further investigations.
感染是在患有急性白血病(急性淋巴细胞白血病和急性非淋巴细胞白血病)的儿童中应用高度积极的联合细胞毒性疗法过程中并发症的常见原因。根据配对系统,对患有急性淋巴细胞白血病和急性非淋巴细胞白血病的儿童感染病例(24例接受静脉注射免疫球蛋白治疗,24例未接受该治疗)进行了静脉注射免疫球蛋白(IVIG)辅助治疗效果的研究。将多价功能完整的单体静脉注射免疫球蛋白“Endobulin”Immuno,100mg/kg应用于感染——发热发作,如有可能,联合针对性抗生素治疗。结果表明,接受静脉注射免疫球蛋白治疗的儿童发热发作次数在统计学上显著减少(p<0.01),发热天数也减少(p<0.05)。尽管所获得的结果表明在应用这种越来越重要的支持性治疗时这种治疗可能性是有利的,但作者得出结论,该疗法价值的最终评估仍未确定,需要进一步研究。